Eli Lilly Announces CFO Change
Eli Lilly Announces CFO Change
Shares of Eli Lilly And Company (NYSE:LLY) announced that its Chief Financial Officer, Anat Ashkenazi, has resigned to pursue a new career. Gordon Brooks has been appointed as the interim CFO, effective July 15 2024. The company is actively searching for a permanent replacement.
Lilly and Company股票(NYSE:LLY)的財務總監Anat Ashkenazi宣佈辭職，追求新的工作機會。 Gordon Brooks被任命爲暫代財務總監，自2024年7月15日起生效。該公司正在積極尋找永久替代人選。
What Else: Additionally, Eli Lilly's shares are being closely watched due to a circulating article highlighting a high number of patients quitting Ozempic, a weight loss drug, due to severe side effects. This issue has impacted the broader market sentiment around weight loss medications, with lawsuits alleging severe side effects like stomach paralysis and blindness according to DailyMail.
其他：此外，由於一篇文章指出大量患者因副作用嚴重而退出減肥藥Ozempic，Eli Lilly的股票受到密切關注。這個問題影響了整個減肥藥市場的情緒，據DailyMail報道，有人提出訴訟，稱出現了嚴重的副作用，如胃麻痹和失明。
LLY Price Action: Eli Lilly and Company shares were slightly up, trading 0.80% higher at $940.00 at the time of writing, according to Benzinga pro.
LLY股票價格變動：根據Benzinga Pro的消息，在撰寫本文時，Eli Lilly and Company的股票稍微上漲，漲幅爲0.80%，報940.00美元。
Photo by rafapress on Shutterstock.
照片來自Shutterstock的rafapress。